| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| In-process research and development | 73,400,000 | |||
| Total other assets | 73,400,000 | |||
| Prepaid expenses | 1,100,000 | |||
| Inventory | 17,208,967 | |||
| Cash and cash equivalents | 112 | |||
| Total current assets | 18,309,079 | |||
| Total assets | 91,709,079 | |||
| Due to related party-Related Party | 7,464,362 | |||
| Accrued expenses | 8,458,554 | |||
| Accounts payable | 8,667,419 | |||
| License payable | 28,400,000 | |||
| Total current liabilities | 52,990,335 | |||
| Note payable to related party-Related Party | 3,800,111 | |||
| Deferred tax liability | 2,520,720 | |||
| Total liabilities | 59,311,166 | |||
| Accumulated deficit | -59,043,300 | |||
| Common stock - 0.0001 par value 400,000,000 and 100,000,000 shares authorized at june 30, 2025 and september 30, 2024, respectively 71,552,402 shares issued and outstanding | 7,155 | |||
| Additional paid-in capital | 91,434,058 | |||
| Total stockholders equity | 32,397,913 | |||
| Total liabilities and stockholders equity | 91,709,079 | |||
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)